Mediwound (MDWD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MediWound has reported a significant milestone with FDA approval for pediatric use of its burn treatment, NexoBrid, while also progressing with its Phase 3 trial for EscharEx targeting venous leg ulcers. Despite a decrease in quarterly revenue to $4.4 million and a notable increase in net loss primarily due to warrant revaluation, the company secured substantial financing, including a $25 million PIPE investment and €16.25 million from the EIC, to bolster its financial position and expand its manufacturing capabilities.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
